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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to a 
combination of diosmin, troxerutin and hesperidin and maintenance of 
normal venous tone pursuant to Article 13(5) of Regulation (EC) No 
1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Omikron Italia S.r.l., submitted pursuant to  Article 13.5 of Regulation (EC) 
No 1924/2006 via the Competent Authority of Italy, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to a combination 
of diosmin, troxerutin and hesperidin and maintenance of normal venous tone. The food that is a subject of the 
health claim, a combination of diosmin, troxerutin and hesperidin, is sufficiently characterised. The claimed 
effect, maintenance of normal venous tone, is a beneficial physiological effect. No human intervention studies 
from  which  conclusions  could  be  drawn  for  the  scientific  substantiation  of  the  claim  were  provided  by 
the applicant.  The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between 
the consumption of a combination of diosmin, troxerutin and hesperidin and the maintenance of normal venous 
tone. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from Omikron Italia S.r.l, submitted pursuant to Article 13(5) of Regulation 
(EC) No 1924/2006 via the Competent Authority of Italy, the Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to a combination of diosmin, troxerutin and hesperidin and maintenance of normal venous 
tone. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application includes a request for the protection of proprietary data. 
The food that is the subject of the health claim is a combination of diosmin, troxerutin and hesperidin 
in the form of a tablet.  
The claimed effect proposed by the applicant is “maintenance of physiological venous tone”. The 
target population proposed by the applicant is “subjects presenting fatigability and feeling heaviness in 
the lower limbs, predisposition to capillary fragility and to alteration of venous-capillary homeostasis, 
due to environmental factors or wrong lifestyle as prolonged standing and excessive nearness to heat 
sources”. 
EFSA requested the applicant to identify the specific physiological function of the body that is the 
subject of the claim, together with the outcome measures that may be used for the scientific evaluation 
of that function. The applicant stated that “physiological venous tone ensures physiological venous 
return from peripheral capillaries to the heart” and that the product “improved capillary permeability 
in in vitro study”, which “can be measured in humans as reduction of feeling of heaviness, burning, 
cramps, formication in the lower limbs”. 
The Panel considers that measurement of a reduction in the feeling of heaviness, burning, cramps and 
formication in the lower limbs is not a direct measure of “venous tone”. 
The Panel considers that the health claim refers to the maintenance of normal physiological venous 
tone in healthy adults without signs or symptoms of chronic venous insufficiency (CVI) and does not 
include the treatment of CVI. 
The  Panel  considers  that  the  maintenance  of  normal  physiological  venous  tone  is  a  beneficial 
physiological effect. 
The applicant identified nine human studies, six reviews, three animal studies and one in vitro study as 
pertinent to the health claim. Only the in vitro study was performed with the food (i.e. a combination 
of diosmin, troxerutin and hesperidin) which is the subject of the claim. 
No human intervention study was performed with the food that is the subject of the claim. 
The  Panel  considers  that,  in  the  absence  of  evidence  of  an  effect  of  a  combination  of  diosmin, 
troxerutin and hesperidin on the maintenance of venous tone in humans, the results of the in vitro 
study cannot be used as a source of data for the scientific substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of diosmin, troxerutin and hesperidin and 
maintenance of normal venous tone. A combination of diosmin, troxerutin and hesperidin and venous tone 
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BACKGROUND 
Regulation (EC) No 1924/2006
4 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As  a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14  thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children ’s  development  and  health)  which  are  based  on  newly  developed 
scientific evidence, or which include a request for the protection of proprietary data, to the Community 
list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted  claims  referred  to  in  Article 13(3)  shall  be  submitted  by  the  applicant  to  the  national 
competent authority  of a Member  State,  which  will  make  the  application  and  any  supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
  The application was received on 15/04/2013. 
  The  scope  of  the  application  was  proposed  to  fall  under  a  health  claim  based  on  newly 
developed scientific evidence. 
  On 21/05/2013, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
  On 17/06/2013, EFSA received the missing information as submitted by the applicant. 
  The scientific evaluation procedure started on 10/07/2013. 
  On 25/09/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 02/10/2013 and restarted on 16/10/2013, in compliance with Article 18(3) of 
Regulation (EC) No 1924/2006. 
  On  16/10/2013,  EFSA  received  the  requested  information  (which  was  made  available  to 
EFSA in electronic format on 15/10/2013). 
  During  its  meeting  on  11/12/2013,  the  NDA  Panel,  having  evaluated  the  data  submitted, 
adopted an opinion on the scientific substantiation of a health claim related to a combination 
of diosmin, troxerutin and hesperidin and maintenance of normal venous tone. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion 
on the scientific substantiation of a health claim related to a combination of diosmin, troxerutin and 
hesperidin and maintenance of normal venous tone. 
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. A combination of diosmin, troxerutin and hesperidin and venous tone 
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EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of a combination of diosmin, troxerutin and hesperidin, a positive assessment of its safety or a decision 
on whether a combination of diosmin, troxerutin and hesperidin is, or is not, classified as a foodstuff. 
It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 
1924/2006. 
It should also be highlighted that the scope and the proposed wording of the claim and the conditions 
of  use  as  proposed  by  the  applicant  may  be  subject  to  changes,  pending  the  outcome  of  the 
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. A combination of diosmin, troxerutin and hesperidin and venous tone 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Omikron Italia S.r.l., Viale Bruno Buozzi, 5, 00197 Roma, Italy. 
The application includes a request for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006 (information on manufacturing process and Bartoli et al. (2010) 
study). 
Food/constituent as stated by the applicant 
According to the applicant, the food for which this health claim is made is a combination of diosmin 
(300 mg), troxerutin (300 mg) and hesperidin (100 mg) in the form of a tablet. 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect is a physiological stabilising action on the interstitial 
connective tissue of vessels and on the inflammatory process. Flavonoids have several effects on 
vessels and on inflammatory processes. In particular, diosmin has proven to be the more effective 
molecule to maintain physiological venous tone, to reinforce capillary resistance, to prevent stasis and 
to protect against free radicals. Hesperidin, owing to its action on prostaglandin synthesis inhibition, is 
the most powerful flavonoid in protecting the endothelium from inflammation and pain. Troxerutin 
has proven to be the more effective molecule, among the flavonoids, in maintaining physiological 
venous capillary permeability. The vasotonic action is mediated by an increase in the sympathetic 
effect mediated by noradrenaline on the venous wall with an improvement in the normal contractile 
response, through the synergic action of three components of the flavonoid mixture. 
Wording of the health claim as proposed by the applicant 
The  applicant  has  proposed  the  following  wording  for  the  health  claim:  “the  flavonoid  mixture 
containing 300 mg of diosmin, 300 mg of troxerutin and 100 mg of hesperidin is a useful co adjuvant 
in maintaining physiological venous tone”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed an intake of one tablet per day of a combination of diosmin (300 mg), 
hesperidin (300 mg) and troxerutin (100 mg). The target population proposed is subjects presenting 
with fatigue and a feeling of heaviness in the lower limbs and a predisposition to capillary fragility and 
alteration in the venous capillary homeostasis, as a result of environmental factors or an inappropriate 
lifestyle, such as prolonged standing and excessive nearness to sources of heat. In these subjects, the 
intake of diosmin, troxerutin and hesperidin helps to maintain the trophism of the venous capillary 
circulation and to prevent vascular dysfunction. Children and pregnant and lactating women should 
avoid consumption of the food that is the subject of this health claim. 
ASSESSMENT 
1.  Characterisation of the food 
The food that is the subject of the health claim is a combination of diosmin, troxerutin and hesperidin. 
Diosmin is a semi-synthetic substance (modified hesperidin) with the chemical name: 5-hydroxy-2-(3-
hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-
trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one,  with  chemical  formula 
C28H32O15 and molecular mass 608. 
Troxerutin  (chemical  name:  2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-4-
oxo-4H-chromen-3-yl-6-O-(6-deoxy-β-D-mannopyranosyl)-β-D-glucopyranoside)  is  a 
trihydroxyethylated derivative of the natural flavonoid rutin with chemical formula  C33H42O19 and 
molecular mass 742. It is present in tea, coffee, cereal grains and a variety of fruits and vegetables. A combination of diosmin, troxerutin and hesperidin and venous tone 
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Hesperidin (chemical name: (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-3,4-dihydro-2H-
chromen-7-yl-6-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside),  with  chemical  formula 
C28H34O15 and molecular mass 610, is a flavanone glycoside constituting the main flavonoid in citrus 
fruits.  
One tablet contains 300 mg diosmin, 300 mg troxerutin and 100 mg hesperidin. 
Information  about  the  manufacturing  process,  control  specifications,  stability  and  batch-to-batch 
variability has been provided. 
The Panel considers that the food, a combination of diosmin, troxerutin and hesperidin, which is the 
subject of the health claim, is sufficiently characterised. 
2.  Relevance of the claimed effect on human health 
The claimed effect proposed by the applicant is “the maintenance of physiological venous tone”. The 
target population proposed by the applicant is “subjects presenting fatigability and feeling heaviness in 
the lower limbs, predisposition to capillary fragility and to alteration of venous-capillary homeostasis, 
due to environmental factors or wrong lifestyle as prolonged standing and excessive nearness to heat 
sources”. 
EFSA requested that the applicant identify the specific physiological function of the body that is the 
subject  of  the  claim,  together  with  the  outcome  measures  which  may  be  used  for  the  scientific 
evaluation of that function. The applicant stated that “physiological venous tone ensures physiological 
venous  return  from  peripheral  capillaries  to  the  heart”  and  that  the  product  “improved  capillary 
permeability  in  in  vitro  study”,  which  “can  be  measured  in  humans  as  reduction  of  feeling  of 
heaviness, burning, cramps, formication in the lower limbs”. 
The Panel considers that measurement of a reduction in the feeling of heaviness, burning, cramps and 
formication in the lower limbs is not a direct measure of “venous tone”. 
The Panel considers that the health claim refers to the maintenance of normal venous tone in healthy 
adults without signs or symptoms of chronic venous insufficiency (CVI) and does not include the 
treatment of CVI. 
The  Panel  considers  that  the  maintenance  of  normal  physiological  venous  tone  is  a  beneficial 
physiological effect. 
3.  Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed looking for publications related to marketed 
flavonoid formulations containing at least one of the functional substances present in the combination 
of diosmin, troxerutin and hesperidin, which is the subject of the claim. Then a manual selection of 
papers was performed taking into consideration “the pertinence of the effect on the target population 
for which the claim is intended”. The inclusion and exclusion criteria and the time-frame were not 
presented. The Panel notes that the search strategy was inadequately described, despite a request by 
EFSA to provide more detailed information about the search strategy. 
The applicant identified nine human studies, six reviews, three animal studies and one in vitro study as 
pertinent to the health claim. Only the in vitro study was performed with a combination of foods which 
is the subject of the claim. 
In six human studies, the effect of different flavonoids (diosmin and beta-hydroxyethyl-rutosides, 
beta-hydroxyethyl-rutosides,  diosmin  and  hesperidin,  and  micronised  purified  flavanoid  fraction 
(MPFF) consisting of diosmin and hesperidin) on symptoms of chronic venous disease was evaluated 
(Jantet, 2000; Danielsson et al., 2002; Jantet et al., 2002; Cesarone et al., 2006; Belcaro et al., 2008; A combination of diosmin, troxerutin and hesperidin and venous tone 
 
 
8  EFSA Journal 2014;12(1):3512 
Stuard et al., 2008). Other studies were related to pharmacokinetic aspects (Kienzler et al., 2002; 
Kanaze et al., 2007) and the methods of detection of flavonoids in the human body (Spanakis et al., 
2008) and did not address the effects of the food which is the subject of the claim. 
No human intervention study was performed with the food that is the subject of the claim. 
The  Panel  considers  that,  in  the  absence  of  evidence  of  an  effect  of  a  combination  of  diosmin, 
troxerutin and hesperidin on the maintenance of venous tone in humans, the results of the in vitro 
study (Bartoli et al., 2010) cannot be used as a source of data for the scientific substantiation of the 
claim. 
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between 
the consumption of a combination of diosmin, troxerutin and hesperidin and maintenance of normal 
venous tone. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
  The food product, a combination of diosmin, troxerutin and hesperidin, which is the subject of 
the health claim, is sufficiently characterised. 
  The  claimed  effect  is  “maintenance  of  physiological  venous  tone”.  The  proposed  target 
population  is  “subjects  presenting  fatigability  and  feeling  heaviness  in  the  lower  limbs, 
predisposition to capillary fragility and to alteration of venous-capillary homeostasis, due to 
environmental factors or wrong lifestyle as prolonged standing and excessive nearness to heat 
sources”. Maintenance of normal venous tone is a beneficial physiological effect. 
  A  cause  and  effect  relationship  has  not  been  established  between  the  consumption  of  a 
combination of diosmin, troxerutin and hesperidin and maintenance of normal venous tone. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on a combination of diosmin, troxerutin and hesperidin and maintenance of 
normal venous tone pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 
0381_IT). April 2013. Submitted by Omikron Italia S.r.l. 
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 ABBREVIATIONS 
CVI    chronic venous insufficiency 
MPFF    micronised purified flavanoid fraction 
 